Skip to main content

Table 4 BAL cytological pattern, lung function tests parameters, laboratory results, % of patients on treatment and time from first symptoms to visit 1 in sarcoidosis patients divided according to radiological stage.

From: Exhaled 8-isoprostane as a prognostic marker in sarcoidosis. A short term follow-up

  Stage I Stage II Stage III Difference
BAL lymphocytes (%) 29.6 ± 3.5 34.9 ± 7.3 32.8 ± 7.0 NS
BAL lymphocytes (× 104/mL) 5.03 ± 1.08 8.5 ± 2.7 10.98 ± 4.15 NS
BAL neutrophils (%) 1 ± 0.33
(1) [0-1]
1.13 ± 0.4
(1) [0-2]
0.33 ± 0.21
(0) [0-5]
NS
BAL neutrophils
(× 104/mL)
0.15 ± 0.06 0.22 ± 0.08 0.23 ± 0.22 NS
BAL eosinophils (%) 1.17 ± 0.25
(1) [0.5-1.5]
0.75 ± 0.25
(1) [0-1]
0.72 ± 0.32
(1) [0-5]
NS
BAL eosinophils
(× 104/mL)
0.14 ± 0.03 0.16 ± 0.25 0.72 ± 0.32 p ≤ 0.01: I vs III
p ≤ 0.05: II vs III
FEV1 (% predicted) 99.4 ± 3.5 81.1 ± 7.5 87.8 ± 7.0 p ≤ 0.05: I vs II
FVC (% predicted) 104.7 ± 3.5 84.8 ± 7.0 94.9 ± 4.0 p ≤ 0.05: I vs II
FEV1/FVC (%) 0.83 ± 0.02 0.78 ± 0.04 0.77 ± 0.04 NS
DLCOc (% predicted) 96.8 ± 4.4 77.4 ± 6.0 77.1 ± 6.3 p ≤ 0.05: I vs II&III
SACE (IU/L) 65.8 ± 8.6 98.8 ± 30.3 45.8 ± 12.8 NS
S-Ca2+(mmol/L) 2.46 ± 0.02 2.44 ± 0.08 2.50 ± 0.02 NS
U-Ca2+(mmol/24 h) 5.25 ± 0.48 5.15 ± 0.94 4.52 ± 0.83 NS
CRP (mg/L) 7.30 ± 2.27
(5.0)
[1.5-7.1]
19.85 ± 8.77
(9.4)
[4.6-25.3]
4.40 ± 1.71
(2.5)
[0.7-6.7]
NS
T from onset to V1
(weeks)
38 ± 25
(8) [4-24]
107 ± 50
(8) [4-238]
149 ± 55
(88) [18-289]
p ≤ 0.05: I vs III
LS 15/23 5/9 0/8 -
  1. DLCOc -- diffusion capacity for CO corrected for hemoglobin, FEV1 -- forced expiratory volume in 1st second of expiration, FVC -- forced vital capacity,
  2. LS -- Löfgren syndrome, S -- serum, SACE -- serum angiotensin converting enzyme, T -- time, U -- urine, V1 -- visit 1.